ArticleCancer medicine2026
Early Risk Identification of Sepsis During Induction Chemotherapy in Newly Diagnosed AML: A Nomogram-Based Tool.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPatients with acute myeloid leukemia (AML) experience severe infections frequently during and after chemotherapy. The purpose of this study was to develop an early risk assessment tool to identify newly diagnosed AML patients at high risk of developing sepsis during the early phase of induction chemotherapy.
methodsThe records of 192 newly diagnosed AML patients from February 2017 to December 2023 at our institution were retrospectively reviewed. Kaplan-Meier survival analysis was performed to explore the prognosis difference between groups with or without sepsis. Mann-Whitney U test, Chi-square test, and multivariable logistic regression analysis were used to identify independent risk factors and establish a nomogram for early risk stratification of sepsis. The predictive accuracy of the nomogram was evaluated using the area under the curve (AUC), calibration curves, and concordance index (C-index). The nomogram is intended for application on days 3-5 of induction chemotherapy.
resultsMultivariate logistic regression identified TP53 mutation, elevated aspartate aminotransferase (AST) and C-reactive protein (CRP) at diagnosis, increased procalcitonin (PCT), and higher urea levels post-induction as independent risk factors for sepsis progression. The bootstrap-corrected AUC was 0.892 (C-index 0.892). The bias-corrected calibration curve was close to the ideal line, demonstrating strong consistency between actual observations and predictions. Patients with sepsis experienced a poorer prognosis (p < 0.001) both at 1-year and 5-year survival rates. The incidence rates of pneumonia and invasive fungal infection were higher in the sepsis group.
conclusionsWe developed a nomogram for early identification of sepsis risk in newly diagnosed AML patients during their initial induction chemotherapy. This tool may assist clinicians in identifying patients requiring close monitoring and intensive supportive care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.